The Rise of Specialty Pharmacy Costs

[1]  G. Joyce,et al.  Benefit design and specialty drug use. , 2006, Health affairs.

[2]  D. Lavallee,et al.  Health plans' strategies for managing outpatient specialty pharmaceuticals. , 2006, Health affairs.

[3]  K. Adams.  The off-label conundrum. , 2006, Biotechnology healthcare.

[4]  Marc Cohen,et al.  Managing the expanded use of biologics across therapeutic areas: an example from b-cell targeted therapies. , 2006, The American journal of managed care.

[5]  C. Mullins,et al.  Variability and growth in spending for outpatient specialty pharmaceuticals. , 2005, Health affairs.

[6]  L. Sidiropoulos,et al.  The effect of adherence to therapy on sustained response in daily or three times a week interferon alpha‐2b plus ribavirin treatment of naïve and nonresponder chronic hepatitis C patients , 2005, Journal of viral hepatitis.

[7]  S. Sullivan.  Consensus guidelines for specialty pharmaceuticals: a best-practice approach for cost-effective management. , 2004, American Journal of Managed Care.

[8]  A. Lotvin.  Specialty pharmacy presents unique set of challenges. , 2004, Managed care.

[9]  J. Golenski.  Specialist discretion for managing specialty pharmaceuticals: the ethics argument for discretion. , 2004, The American journal of managed care.

[10]  A. Fendrick,et al.  Effect of off-label use of oncology drugs on pharmaceutical costs: the rituximab experience. , 2003, The American journal of managed care.

[11]  M. Fried.  Side effects of therapy of hepatitis C and their management , 2002 .